NYSEAMERICAN : AEON
AEON Biopharma, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 0.274 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 13.67M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Selling, General & Admin | 12.72M | 12.21M | 13.64M | 19.79M | 13.68M | 11.15M |
| Research & Development | 7.18M | 4.09M | 14.18M | 33.05M | 34.75M | 25.73M |
| Operating Expenses | 19.90M | 16.30M | 27.82M | 52.84M | 48.43M | 36.88M |
| Operating Income | -19.90M | -16.30M | -27.82M | -52.84M | -48.43M | -36.88M |
| Other Non Operating Income (Expenses) | -6.33M | -3.51M | -34.29M | -17.19M | 289.00K | -135.00K |
| EBT Excluding Unusual Items | -26.22M | -19.81M | -62.12M | -70.02M | -48.14M | -37.02M |
| Legal Settlements | -28.97M | |||||
| Other Unusual Items | -28.40M | -19.41M | 104.12M | 33.39M | -4.42M | 10.35M |
| Pretax Income | -54.62M | -39.22M | 42.01M | -384.63M | -52.56M | -55.64M |
| Earnings From Continuing Operations | -54.62M | -39.22M | 42.01M | -384.63M | -52.56M | -55.64M |
| Net Income | -54.62M | -39.22M | 42.01M | -384.63M | -52.56M | -55.64M |
| Net Income to Common | -54.62M | -39.22M | 42.01M | -384.63M | -52.56M | -55.64M |
| Shares Outstanding (Basic) | 28.94M | 9.92M | 540.36K | 77.07M | 1.93M | 1.75M |
| Shares Outstanding (Diluted) | 28.94M | 9.92M | 575.95K | 77.07M | 1.93M | 1.75M |
| EPS (Basic) | -1.89 | -3.95 | 77.74 | -4.99 | -27.25 | -31.73 |
| EPS (Diluted) | -1.89 | -3.95 | 72.93 | -4.99 | -27.25 | -31.73 |
| Free Cash Flow | -13.64M | -17.31M | -20.29M | -47.83M | -35.89M | -28.60M |
| Free Cash Flow Per Share | -0.47 | -1.75 | -35.23 | -0.62 | -18.61 | -16.31 |
| EBITDA | -19.82M | -16.22M | -27.73M | -52.74M | -48.36M | -36.88M |
| D&A For EBITDA | 78.00K | 78.00K | 97.00K | 99.00K | 68.00K | 3.00K |
| EBIT | -19.90M | -16.30M | -27.82M | -52.84M | -48.43M | -36.88M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 3.43M | 3.01M | 13.00K | 5.16M | 9.75M | 5.13M |
| Cash & Short-Term Investments | 3.43M | 3.01M | 13.00K | 5.16M | 9.75M | 5.13M |
| Prepaid Expenses | 562.00K | 392.00K | 1.58M | 1.06M | 92.00K | 26.00K |
| Total Current Assets | 3.99M | 3.40M | 1.59M | 6.22M | 9.84M | 5.15M |
| Property, Plant & Equipment | 1.05M | 1.21M | 1.52M | 594.00K | 906.00K | 922.00K |
| Other Long-Term Assets | 863.00K | 948.00K | 29.00K | 29.00K | 34.00K | 360.00K |
| Total Assets | 5.91M | 5.56M | 3.14M | 6.84M | 10.78M | 6.44M |
| Accounts Payable | 2.70M | 942.00K | 5.91M | 3.39M | 7.80M | 1.19M |
| Accrued Expenses | 4.38M | 5.70M | 8.12M | 9.38M | 3.65M | 4.01M |
| Current Portion of Long-Term Debt | 70.87M | 15.60M | ||||
| Current Portion of Leases | 263.00K | 252.00K | 121.00K | 278.00K | 257.00K | |
| Total Current Liabilities | 7.34M | 6.90M | 14.15M | 13.05M | 82.57M | 20.80M |
| Long-Term Debt | 1.75M | 34.60M | 11.69M | 60.43M | 70.76M | |
| Long-Term Leases | 757.00K | 893.00K | 1.15M | 242.00K | 524.00K | |
| Other Long-Term Liabilities | 11.42M | 18.20M | 4.73M | 146.84M | 221.00K | |
| Total Liabilities | 21.27M | 60.59M | 31.71M | 159.89M | 143.24M | 92.31M |
| Common Stock | 10.00K | 9.00K | 4.00K | 4.00K | 14.00K | 14.00K |
| Additional Paid-In Capital | 468.40M | 415.78M | 403.02M | 381.26M | 187.35M | 187.35M |
| Retained Earnings | -483.77M | -470.82M | -431.60M | -473.60M | -474.84M | -422.28M |
| Treasury Stock | -23.00K | -23.00K | ||||
| Comprehensive Income & Other | -60.71M | |||||
| Total Common Equity | -15.36M | -55.03M | -28.57M | -153.04M | -287.50M | -234.94M |
| Minority Interest | 17.09M | 11.12M | ||||
| Shareholders' Equity | -15.36M | -55.03M | -28.57M | -153.04M | -132.46M | -85.88M |
| Total Liabilities & Equity | 5.91M | 5.56M | 3.14M | 6.84M | 10.78M | 6.44M |
| Total Debt | 2.77M | 35.74M | 12.96M | 278.00K | 131.79M | 86.89M |
| Net Cash (Debt) | 656.00K | -32.74M | -12.94M | 4.88M | -122.05M | -81.76M |
| Net Cash Per Share | 0.02 | -3.30 | -22.47 | 0.06 | -63.29 | -46.63 |
| Filing Date Shares Outstanding | 49.88M | 25.30M | 10.53M | 548.92K | 1.93M | 1.93M |
| Total Common Shares Outstanding | 26.31M | 12.11M | 555.51K | 516.11K | 1.93M | 1.93M |
| Working Capital | -3.35M | -3.50M | -12.56M | -6.83M | -72.74M | -15.65M |
| Book Value Per Share | -0.58 | -4.55 | -51.43 | -296.54 | -149.11 | -121.85 |
| Tangible Book Value | -15.36M | -55.03M | -28.57M | -153.04M | -287.50M | -234.94M |
| Tangible Book Value Per Share | -0.58 | -4.55 | -51.43 | -296.54 | -149.11 | -121.85 |
| Machinery | 440.00K | 440.00K | 436.00K | 436.00K | 436.00K | 130.00K |
| Leasehold Improvements | 66.00K | 66.00K | 66.00K | 66.00K | 66.00K | 66.00K |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Net Income | -54.62M | -39.22M | 42.01M | -384.63M | -52.56M | -55.64M |
| Depreciation & Amortization | 78.00K | 78.00K | 97.00K | 99.00K | 68.00K | 3.00K |
| Other Amortization | 331.00K | 1.98M | ||||
| Asset Writedown & Restructuring Costs | 348.00M | |||||
| Stock-Based Compensation | 5.60M | 5.32M | 6.25M | 7.00M | 5.89M | 5.22M |
| Other Operating Activities | 35.14M | 23.46M | -69.35M | -15.55M | 4.41M | 18.59M |
| Change in Accounts Payable | -1.21M | -4.97M | 2.52M | -4.59M | 6.61M | -898.00K |
| Change in Other Net Operating Assets | 1.38M | -1.97M | -1.82M | 1.85M | -345.00K | 2.31M |
| Operating Cash Flow | -13.64M | -17.31M | -20.29M | -47.83M | -35.58M | -28.43M |
| Capital Expenditures | -4.00K | -306.00K | -170.00K | |||
| Investing Cash Flow | -4.00K | -306.00K | -170.00K | |||
| Long-Term Debt Issued | 15.00M | 14.00M | 44.50M | 15.00M | ||
| Long-Term Debt Repaid | -3.99M | |||||
| Total Debt Repaid | -3.99M | |||||
| Net Debt Issued (Repaid) | 15.00M | 14.00M | 40.51M | 15.00M | ||
| Issuance of Common Stock | 2.63M | 18.51M | 147.00K | |||
| Other Financing Activities | 6.00M | 1.79M | -1.44M | |||
| Financing Cash Flow | 8.63M | 20.30M | 15.15M | 14.00M | 40.51M | 13.56M |
| Net Cash Flow | -5.01M | 2.99M | -5.14M | -33.83M | 4.62M | -15.04M |
| Free Cash Flow | -13.64M | -17.31M | -20.29M | -47.83M | -35.89M | -28.60M |
| Free Cash Flow Per Share | -0.47 | -1.75 | -35.23 | -0.62 | -18.61 | -16.31 |
| Levered Free Cash Flow | -7.19M | -11.00M | -10.30M | -25.48M | -16.79M | -14.85M |
| Unlevered Free Cash Flow | -7.19M | -11.00M | -10.30M | -25.48M | -16.79M | -14.85M |
| Change in Working Capital | 169.00K | -6.94M | 706.00K | -2.74M | 6.27M | 1.42M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 13.62M | 13.02M | 21.58M | 267.55M | 1.40B | 213.58M |
| Enterprise Value | 12.96M | 25.35M | 37.55M | 251.72M | 1.64B | 428.37M |
| Last Close Price | 0.27 | 1.10 | 38.88 | 518.40 | 723.60 | 699.12 |
| PE Ratio | 0.51 | |||||
| PB Ratio | -0.24 | -0.76 | -1.75 | -10.53 | -2.49 | |
| Debt / Equity Ratio | -0.18 | -0.65 | -0.45 | -0.00 | -0.99 | -1.01 |
| Net Debt / Equity Ratio | 0.04 | -0.59 | -0.45 | 0.03 | -0.92 | -0.95 |
| Net Debt / EBITDA Ratio | 0.03 | -2.02 | -0.47 | 0.09 | -2.52 | -2.22 |
| Net Debt / FCF Ratio | 0.05 | -1.89 | -0.64 | 0.10 | -3.40 | -2.86 |
| Quick Ratio | 0.47 | 0.44 | 0.00 | 0.40 | 0.12 | 0.25 |
| Current Ratio | 0.54 | 0.49 | 0.11 | 0.48 | 0.12 | 0.25 |
| Return on Assets (ROA) | -141.53% | -234.17% | -348.25% | -374.77% | -351.67% | -166.73% |
| Return on Capital Employed (ROCE) | 1,389.40% | 1,219.30% | 252.80% | 851.60% | 67.50% | 256.70% |
| Earnings Yield | -691.31% | -301.19% | 194.61% | -143.76% | -3.77% | -26.05% |
| FCF Yield | -100.18% | -132.94% | -94.01% | -17.88% | -2.57% | -13.39% |
| Buyback Yield / Dilution | -613.82% | -1,622.66% | 99.25% | -3,896.62% | -9.98% | -1,813.85% |